Skip to content
AnalystLens

MCKESSON CORP Annual Report, Year Ended Mar 31, 1996

Filing Date
Filed June 19, 1996
Period End
March 31, 1996
Security
MCK
In the record · 2016–202610-K1110-Q328-K146

MCK filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 146 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’17Mar ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Apr ’21Apr ’21
  4. FY2025 annual report10-K · May ’25May ’25

01—Abstract

Summary

Summary of the 10-K filed June 19, 1996. Cited figures are marked; the original filing is the authoritative source.

McKesson Corporation's fiscal 1996 10-K (year ended March 31, 1996) describes a company restructured after the July 1994 spin-off of its pharmaceutical benefits management business (PCS), which was sold to Eli Lilly for approximately $4 billiona and is reported as a discontinued operation.

The continuing company is organized around four segments: Health Care Services (the core, centered on pharmaceutical wholesale distribution in the U.S. and Canada, plus a 22.7%b stake in Nadro of Mexico, the Pharmaceutical Services Group, and Sunmark/Zee Medical/Automated Healthcare), Service Merchandising (Millbrook), Water Products (Sparkletts and Alhambra bottled water), and Armor All (55%-owned automotive and home care products). Management is explicitly tilting the company toward health care, with fiscal 1996 acquisitions including Ogden BioServices (renamed McKesson Bioservices) and Automated Healthcare, and internal technology investments such as OmniLink, CareMax, BidLink, and SupplyNET. The filing is notable for capital return and concentration risk.

The company repurchased 1.35 million shares for $63 millionc in fiscal 1996, substantially completed an initial 3.5 million share buyback, and on May 31, 1996 authorized a new repurchase of another 3.5 million shares. Wal-Mart accounted for 11% of consolidated revenues in fiscal 1996, and the Health Care Services wholesale business requires large inventories financed substantially by related payables. Shares outstanding were roughly 42.9 million as of June 3, 1996, with non-affiliate market value of about $1.45 billion.

The main legal and environmental exposures are a set of antitrust class actions by retail pharmacies alleging brand-name drug price fixing, in which the company was granted summary judgment in MDL 997 and faces remaining cases that it says it will defend vigorously. Under a judgment-sharing agreement, manufacturers indemnify wholesalers above $1 milliond per defendant. Environmental reserves cover roughly $24 million for five former chemical-operation sites and about $4 million for Superfund and other matters.

Management believes none of these matters will have a material adverse effect. The financial figures themselves are incorporated by reference to the Appendix and were not included in the excerpt provided, so this summary does not cite specific revenue, earnings, or margin numbers.

02—Key points

Key Highlights

  1. Post-spin-off McKesson is a four-segment company, with Health Care Services as the strategic core after the ~$4 billion sale of the PCS business to Eli Lilly, which is treated as discontinued operations.
  2. Health Care Services includes the largest U.S. and Canadian drug wholesale distribution business, a 22.7% equity stake in Mexico's Nadro, and the Valu-Rite program serving about 5,050 independent pharmacies.
  3. Fiscal 1996 acquisitions were Ogden BioServices (renamed McKesson Bioservices, December 1995) and Automated Healthcare (April 1996), with stakes in two technology-focused companies.
  4. Capital return is active: 1.35 million shares repurchased for $63 million in fiscal 1996, and a new authorization of 3.5 million shares announced May 31, 1996.
  5. Customer concentration: Wal-Mart represented 11% of consolidated fiscal 1996 revenues, up from 10% in fiscal 1995.
  6. Armor All is 55% owned, and $180 million of exchangeable debentures could reduce the stake to roughly 22% and limit McKesson's control if exchanged.
  7. Legal exposure centers on brand-name drug price-fixing antitrust class actions brought by retail pharmacies, with summary judgment granted in MDL 997 and manufacturer indemnification above $1 million per wholesaler; environmental reserves total roughly $24 million for five sites plus about $4 million for Superfund and other matters.

03—Questions

Frequently Asked Questions

  1. What is the nature of McKesson's business after the 1994 restructuring?

    After the PCS sale to a subsidiary of Eli Lilly for about $4 billion, the continuing company is a diversified distributor and services business. Its largest segment, Health Care Services, is a U.S. and Canadian pharmaceutical and health care wholesaler with added pharmacy technology and pharmaceutical services. The other segments are Service Merchandising (Millbrook), Water Products, and Armor All.

  2. How significant is the Health Care Services wholesale business to the company's balance sheet?

    The wholesale business requires large inventories, and the filing states that a significant portion is financed by related payables, which means working capital depends heavily on supplier credit. The filing does not quantify this in the excerpt, so the actual inventory and payables figures should be checked in the Appendix financial statements.

  3. What are the main litigation risks investors should understand?

    The most prominent risk is a group of antitrust suits by retail pharmacies alleging that wholesalers and manufacturers conspired to fix brand-name drug prices. The company won summary judgment in MDL 997 and was dismissed without prejudice in K-S Pharmacies, while other cases remain pending. Manufacturers have agreed to hold wholesalers harmless above $1 million per defendant, which limits exposure. Management says it has meritorious defenses and expects no material adverse effect.

  4. Is McKesson returning capital to shareholders?

    Yes. The company repurchased 1.35 million shares for $63 million in fiscal 1996, substantially completed its initial 3.5 million share program, and on May 31, 1996 authorized another 3.5 million shares. Dividend details are in the Appendix, which is incorporated by reference.

  5. What are the company's environmental liabilities?

    Management estimates the upper limit of reasonably possible remediation costs at five former chemical-operation sites at about $24 million, net of third-party contributions, and the company holds Superfund liability estimates of about $3 million across 27 sites plus $1 million for other matters. These amounts are included in recorded reserves, and the filing states that environmental capital expenditures were not material in fiscal 1996.

04—Continue

← View all 10-K filings